New hope for advanced lung cancer patients: drug combo targets tumors after first treatment fails
NCT ID NCT07244926
First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 21 times
Summary
This study tests a combination of two drugs, Sac-TMT and bevacizumab, in 31 adults with advanced non-squamous lung cancer that has worsened after initial chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progression. Participants must have certain genetic markers and cannot have specific gene mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.